tbuckley/cabot-search huggingface dataset:
Surgical management of complex residual masses following systemic chemotherapy for metastatic testicular germ cell tumours
Authors: A. Heidenreich, F. Haidl, P. Paffenholz, Ch. Pape, U. Neumann, D. Pfister
Journal: Annals of Oncology (2016)

Post-chemotherapy retroperitoneal lymphadenectomy (PC-RPLND) represents the treatment of choice in patients with residual masses following chemotherapy for metastatic germ cell tumours. Involvement of major retroperitoneal vessels or thoracic/lumbar spine is rare and challenging but needs complete resection for curative intent. We report on our experience in the management of such complex cases.A total of 185 patients underwent PC-RPLND and we identified 25 (13.5%) patients who needed complex adjunctive vascular (n = 16, 8.6%), skeletal (n = 5, 2.7%) and pancreaticoduodenal (n = 4, 2.2%) surgeries. We performed a retrospective analysis of treatment-associated complications according to the Clavien-Dindo classification. Progression-free, cancer-specific and overall survival was calculated.All patients were of intermediate/poor prognosis according to IGCCCG. Median tumour diameter at time of surgery was 18.6 (9.0-35) cm. Sixteen (8.6%) underwent vascular surgery including aortic resection and replacement, complete or partial resection of the inferior vena cava with thrombectomy, and resection and replacement of the iliac vessels. In five patients, 1-2 metastatic lumbar vertebral bodies were resected, stabilized and replaced. Four patients underwent en-bloc resection of a suprahilar mass with pancreas and duodenum. Pathohistology revealed vital cancer in five patients; teratoma and malignant somatic transformation was identified in 12 and 6 patients, respectively. Complications occurred more often in the group of complex RPLND (41.7 versus 7.2%, P = 0.02) with the majority representing grade I-IIa. After a median follow-up of 28.5 months, four patients developed recurrent disease and one patient died of the disease.Few patients with advanced GCT need complex vascular, skeletal or intestinal surgery in an interdisciplinary setting with good functional and oncological outcome. Due to the complexity, treatment should be performed at specialized centres.
Flagellin, a TLR5 Agonist, Reduces GvHD in Allogeneic HSCT Recipients While Enhancing Anti-Viral Immunity: A Novel Therapeutic Approach
Authors: Mohammad S Hossain, David L Jaye, Brian P Pollack, Alton B Farr, John Roback, Andrew T Gewirtz, Edmund K Waller
Journal: Blood (2011)
SAT0086 The Short-Term and Long-Term of Humeral Immune Responses To Hepatitis B Vaccination Are Impaired in Rheumatoid Arthritis Patients Receiving Conventional and Biological Disease Modifying Anti-Rheumatic Drugs
Authors: S. Intongkam, M. Muthanugulwong, R. Pakchotanon, P. Narongroeknawin, P. Asavanabodee, S. Chaiamnuay
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Hepatitis B vaccination is recommended for rheumatoid arthritis (RA) patients in many international guideline. However, the short-term and long-term efficacies of hepatitis B vaccination in RA patients that recieved conventional and/or biological disease-modifying anti-rheumatic drugs (cDMARDs and/or bDMARDs) are not clearly established. <h3>Objectives</h3> To assess the long term of immunogenicity of the hepatitis B vaccination in rheumatoid arthritis (RA) patients receiving cDMARDs and/or bDMARDs. <h3>Methods</h3> The study comprised 45 patients with RA, of whom 33 received cDMARDs and 12 received bDMARDs therapy (study group), and 9 subjects with age- and sex-matched healthy controls (control group). All subjects were vaccinated with 20 μg of recombinant hepatitis B vaccine (Euvax B®) at weeks 0, 4, and 24. Blood samples were collected 8 weeks and 12 months after receipt of the third vaccine dose to test for antibody to hepatitis B surface antigen (anti-HBs). Responders (seroprotection) were defined as anti-HBs level ≥10 mIU/mL. The study was approved by the ethic committee and institutional review board. <h3>Results</h3> Baseline characteristics of study and control groups were similar. Patients receiving cDMARDs tended to has lower proportion of seroprotection than control group (69.7% vs 100%, p=0.09) at 2 months and (57.57% vs 100%, p=0.016) 12 months after receipt of the third vaccine dose. Patients receiving bDMARDs had a significantly lower proportion of seroprotection compared with control group (50% vs 100%, p=0.02) at both 8 weeks and 12 months after receipt of the third vaccine dose. The proportion of seroprotection is significantly decreased between 2 months and 12 months in patients receiving cDMARDs (69.7% vs 57.57%, p=0.044) after completion of the third dose vaccine. <h3>Conclusions</h3> DMARDs both conventional and biological DMARDs therapy impaired short-term and long-term immunogenic response to hepatitis B vaccine. <h3>Disclosure of Interest</h3> None declared
A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction
Authors: Richard A. Lafayette, Pietro A. Canetta, Brad H. Rovin, Gerald B. Appel, Jan Novak, Karl A. Nath, Sanjeev Sethi, James A. Tumlin, Kshama Mehta, Marie Hogan, Stephen Erickson, Bruce A. Julian, Nelson Leung, Felicity T. Enders, Rhubell Brown, Barbora Knoppova, Stacy Hall, Fernando C. Fervenza
Journal: Journal of the American Society of Nephrology (2016)

IgA nephropathy frequently leads to progressive CKD. Although interest surrounds use of immunosuppressive agents added to standard therapy, several recent studies have questioned efficacy of these agents. Depleting antibody-producing B cells potentially offers a new therapy. In this open label, multicenter study conducted over 1-year follow-up, we randomized 34 adult patients with biopsy-proven IgA nephropathy and proteinuria >1 g/d, maintained on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers with well controlled BP and eGFR<90 ml/min per 1.73 m2, to receive standard therapy or rituximab with standard therapy. Primary outcome measures included change in proteinuria and change in eGFR. Median baseline serum creatinine level (range) was 1.4 (0.8-2.4) mg/dl, and proteinuria was 2.1 (0.6-5.3) g/d. Treatment with rituximab depleted B cells and was well tolerated. eGFR did not change in either group. Rituximab did not alter the level of proteinuria compared with that at baseline or in the control group; three patients in each group had ≥50% reduction in level of proteinuria. Serum levels of galactose-deficient IgA1 or antibodies against galactose-deficient IgA1 did not change. In this trial, rituximab therapy did not significantly improve renal function or proteinuria assessed over 1 year. Although rituximab effectively depleted B cells, it failed to reduce serum levels of galactose-deficient IgA1 and antigalactose-deficient IgA1 antibodies. Lack of efficacy of rituximab, at least at this stage and severity of IgA nephropathy, may reflect a failure of rituximab to reduce levels of specific antibodies assigned salient pathogenetic roles in IgA nephropathy.
Crucial Role of Complement Receptor Type 1 On the Accumulation of Complement Component 3 On Erythrocytes in Patients with PNH Treated with Eculizumab
Authors: Masaki Yamamoto, Jun-ichi Nishimura, Makiko Oosato, Satoru Hayashi, Yoshiko Murakami, Taroh Kinoshita, Yuzuru Kanakura
Journal: Blood (2012)
Pre-Transplant Rituximab Is Associated with Reduced Rate of Acute GvHD After RIC-Allosct In Lymphoma Patients: Results From A Retrospective Monocenter Analysis.
Authors: Roberto Crocchiolo, Jean El Cheikh, Luca Castagna, Alix Helvig, Sabine Furst, Catherine Faucher, Alberto Vazquez, Nawel Belmecheri, Angela Granata, Diane Coso, Reda Bouadaballah, Didier Blaise
Journal: Blood (2010)
AB0518 Clinical Thrombotic Manifestations in SLE Patients with and without Antiphospholipid Antibodies: A Ten-Year Follow-Up
Authors: T. Tarr, N. Nagy, E. Cserép, M. Zeher
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Systemic lupus eyrthematosus can bge associated with antiphospholipid syndrome. Years ago our study team investigated the thrombotic risk factors and complications in 272 lupus patients with and without antiphospholipid antibodies. At baseline, three groups were created, an aPL- group with 107 aPL negative patients, an aPL+ group with 81 aPL positive patients without clinical manifestations and a secondary antiphospholipid syndrome (APS) group with 84 aPL+ patients who met the Sapporo criteria. <h3>Objectives</h3> The objective of this study was to investigate of new thrombotic events, SLE activity,.co-morbidities, and mortality in total of 272 lupus patients for ten years of follow up. <h3>Methods</h3> The above mentioned 272 patients with SLE registerered in the Division of Clinical Immunology, University of Debrecen have been followed up prospectively for ten years. <h3>Results</h3> A total of 28 out of the 272 patients were lost to follow up. A total of 22 new thrombotic complicatons occurred, two in the aPL negative group, three in the aPL+ group. New antiphospholipid antibodies appeared in these patients. 77.3% of the new thrombotic complicatins reoccurred in the APS group despite the adequat anticoagulant and/or anti-platlet therapy. SLE activity was the most common in the APL+ group but the difference was not significant. A total of 27 out of 84 APS (32%), 14 out of 81 aPL positive and 10 out of 107 aPL negative patients died during the follow up. The causes of death were thrombotic events or complications in 40.7% in patients with APS. <h3>Conclusions</h3> Our data confirm recurring thrombotic events in lupus patients with antiphospholipid syndrome. Antiphospholipid syndrome seems to negatively influence the survival of the patients with systemic lupus erythematosus. <h3>Disclosure of Interest</h3> None declared
Exome Sequencing Informs Mechanisms of Clinical Resistance to the FLT3-D835 Inhibitor Crenolanib
Authors: Haijiao Zhang, Kevin Matthew Watanabe-Smith, Daniel Bottomly, Beth Wilmot, Shannon K. McWeeney, Hagop M. Kantarjian, Judy Ho, Jeremy Davis, Blake Pond, Gautam Borthakur, Abhijit Ramachandran, Jorge E. Cortes, Robert Collins, Jeffrey W. Tyner
Journal: Blood (2015)
FRI0529 Initial Validation of The Symptoms in Persons at Risk of Rheumatoid Arthritis (SPARRA) Questionnaire: Table 1.
Authors: M.V. Beers-Tas, L.V. Tuyl, B. Maat, W. Hoogland, R. Stack, K. Raza, D.V. Schaardenburg
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> A range of clinical symptoms can be present in people at risk of rheumatoid arthritis (RA). However, information on location, timing, severity and predictive value of symptoms is still largely lacking. The Symptoms in Persons At Risk of Rheumatoid Arthritis (SPARRA) questionnaire has been developed with support of EULAR to provide more insight into these symptoms<sup>1,2</sup>. <h3>Objectives</h3> To validate the SPARRA questionnaire in an international group of arthralgia patients at risk of RA. <h3>Methods</h3> Questions on presence, severity, impact and location of 13 symptoms were derived from a qualitative study in seropositive arthralgia patients<sup>1</sup>. The items are: joint pain or swelling, joint stiffness, burning and tingling sensations, numbness, change in skin colour, muscle cramps, weakness, fatigue, emotional distress, concentration difficulties and sleep problems. Answers are given on an ordinal scale. The number of days with a symptom per month (0, 1–5, 6–15, 16–30 days), severity (none, mild, moderate and severe) and influence on daily activities (no, small, moderate or high impact) were recorded. Finally, patients were asked to describe the pattern of symptom development over time. For this initial analysis of validity, patients were selected from the Dutch arthralgia cohort. We first administered the questionnaire to 30 patients to ask for ambiguities. Thereafter, 46 patients did a test-retest within one week to assess intra-rater agreement using the % agreement and the kappa score. <h3>Results</h3> Feedback on the questionnaire was received from 5/30 patients. There were only minor comments that did not lead to adaptations, such as difficulty distinguishing pain from stiffness (n=1) and difficulty describing muscle cramps (n=1). 46 arthralgia patients were assessed at 2 time points. The rater agreement was moderate to good for most items with kappa9s of 0.42 to 0.93. We also found acceptable percentages of agreement of 65 to 91 (Table 1). Only tingling sensations and numbness scored low in agreement, with kappa9s of 0.37 and 0.15, respectively. The kappa9s were good across the presence, severity and impact of the item categories. Data on clinical variables and follow-up questionnaires to assess the construct and criterion validity will be presented at the congress. <h3>Conclusions</h3> The SPARRA questionnaire seems to be a reliable scale for evaluating symptoms in persons at risk for RA. More follow-up and data from collaborating centers within Europe is necessary for assessment of the construct, criterion and external validity. <h3>References</h3> Stack, Rheumatology 2014; van Tuyl, Musculoskel Care 2015 <h3>Disclosure of Interest</h3> None declared
Use of Society of Thoracic Surgeons Risk Models in the Assessment of Patients Who Underwent a Transcatheter Aortic Valve Replacement
Authors: Fred H. Edwards
Journal: JAMA Cardiology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Older Patients with Acute Myeloid Leukemia (AML) in First Relapse: Impact of Genetics and of Salvage Therapy. A Study of the Acute Leukemia French Association (ALFA)
Authors: Clémentine Sarkozy, Claude Gardin, Nathalie Gachard, Fatiha Merabet, Pascal Turlure, Jean-Valère Malfuson, Cécile Pautas, Jean-Baptiste Micol, Xavier Thomas, Bruno Quesnel, Karine Celli-Lebras, Claude Preudhomme, Christine Terré, Sylvie Chevret, Mauricette Michallet, Catherine Cordonnier, Pierre Fenaux, Dominique Bordessoule, Sylvie Castaigne, Hervé Dombret
Journal: Blood (2011)
Angiogenesis and Osteoclastogenesis Are Mutually Stimulated in Myeloma: A Role for VEGF and Osteopontin.
Authors: Yoichi Tanaka, Masahiro Abe, Masahiro Hiasa, Toshihiro Hashimoto, Shinsuke Kido, Daisuke Inoue, Shuji Ozaki, Keiji Moriyama, Toshio Matsumoto
Journal: Blood (2005)
FRI0294 The Prognosis Intervals for Pts with SSC-ILD Using Discriminant Analysis:
Authors: O.B. Ovsyannikova, S. Glukhova, O. Koneva, V. Lesnyak, L. Ananieva
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Pulmonary alterations are the major cause of mortality in SSc. The most pts develop some degree of lung injury over the course of the disease. <h3>Objectives</h3> to assess predictors of poor prognosis in a single center cohort of SSc pts with interstitial lung disease (ILD) and to build a predictive model of prognosis disease SSc-ILD. <h3>Methods</h3> 77 pts with SSc-ILD were involved in a longitudinal study over a five-year period. We used discriminant analysis and our selection involved missing value. So discriminant analysis was held at 58 pts (4 were men). The mean age was 47±13 years. Pts. were divided into 3 subgroups based on HRCT changes estimated at the entry of the study and at last visit. The mean time between two evaluations was 57±10 months. The 1st group included 13pts with improvement (n=13), 2nd –pts without any changes (n=30) and 3rd – pts with deterioration negative dynamics (n=15). ROC analysis was used for determination of prognostic intervals. <h3>Results</h3> We got the discrimination function that included: ground glass opacities (GGO) (1 – the absents of GGO; 2 – the presents of GGO); index EScSG (the digital value); FVC (FVC ≥75 = 0, FVC &lt;75 = 1); the maximum daily dose of glucocorticoids (the digital value, mg); Gamma globulins (the digital value, %); cyclophosphamide (CYC) (the absence of CYC =0, the treatment of CYC =1); DLco (DLco &lt;52% =0, DLco ≥52 =1). We assessed all parameters at the entry in the study except DLco evaluated after one year of follow up. Based on this analysis the equation was developed. The equation of prognosis is 3.14 GGO + 0,70 index EScSG – 1,326 FVC - 0,1 the maximum daily dose of glucocorticoids + 0,136 Gamma globulins + 1.066 CYC – 1.075 DLCO ≤ 5,8. Value of equation of prognosis to 5.8 corresponds to stabilization or good prognosis and value after 5.8 corresponds to poor prognosis. The equation of prognosis had 86% sensitivity and 56% specificity. The cut-off point 4.7 was represented 65% sensitivity and 67% specificity. The prognosis intervals were following: value of equetion to 4.7 corresponds to good prognosis; value from 4.8 to 5.8 corresponds to stabilization and vaule after 5.8 corresponds to poor prognosis. The mean value of discrimination function for each group is shown in table. <h3>Conclusions</h3> using discrimination analysis we got the prognosis intervals for the pts with SSc. It can give an opportunity to determine the prognosis of SSc-ILD. <h3>Disclosure of Interest</h3> None declared
Thrombopoietin Receptor Agonist (ELTROMBOPAG) for Chronic Immune Thrombocytopenic Purpura (ITP) Treatment: 21 Patients in Only One Center
Authors: Teresa Álvarez Román, Monica Martin Salces, Nora V. Butta, Miguel Canales, Ihosvany Fernandez, Ana de la Rua, Victor Jimenez Yuste
Journal: Blood (2012)
Efficacy and Safety of DepoCyte® (Liposomal Cytarabine) in Patients with CNS Involvement from Non-Hodgkin’s Lymphoma (NHL): A Report on 32 Patients Treated in Spain.
Authors: José A. García-Marco, B. Navarro, E. Ruiz Sanz, L. Palomera, F.J. Capote, A. Fernández de Sevilla, E.G. Sánchez, A. Cantalapiedra, R. Pérez, J.R. Casal, J.D. Mediavilla, F.R. García, Y. Martín, C. Panizo, A.L. Alvarez, T. García, G. Pérez
Journal: Blood (2006)
OC-076 Endoscopic Placement of Fully Covered Self Expanding Metal Stents (FC-SEMS) into the Pancreatic Duct of Patients With Painful Chronic Pancreatitis
Authors: CA Wadsworth, A Sangwaiya, R Rajaratnam, MA Butt, N Phillips, D Bansi, P Vlavianos, D Westaby
Journal: Gut (2016)

<h3>Introduction</h3> Endoscopic placement of plastic stents into the pancreatic duct (PD) has achieved disappointing outcomes in the treatment of painful chronic pancreatitis (CP), when compared to surgery. However, pancreatic bypass surgery or resection is associated with significant morbidity. Recently, FC-SEMS have proven more effective than plastic stents in the management of strictures of the bile duct. We aimed to assess feasibility, safety and efficacity of PD FC-SEMS in the management of painful CP. <h3>Methods</h3> Patients were recruited at a single tertiary UK pancreatobiliary centre. Patients were considered for PD FC-SEMS after demonstration of i) CT/MR imaging criteria of chronic pancreatitis including dilatation of the main PD and ii) characteristic pancreatic pain resistant to analgesia. Patients’ treatment plans were all determined in a MDT meeting. All patients gave informed consent. Visual analogue pain scores and analgesia requirements were documented prior to intervention and at each follow up appointment. At ERCP, PD cannulation was attempted from the major papilla in all cases. In cases of pancreas divisum, or where PD cannulation via the major papilla failed, cannulation of the minor papilla was attempted. On cannulation of the PD, a pancreatic sphincterotomy was performed before deployment of a 60 mm by 8 mm FC-SEMS. Stent removal was scheduled between 10 and 14 weeks after placement. <h3>Results</h3> 35 patients (22 M) had FC-SEMS placed into the PD. The median age at time of stent placement was 55 y (range 21–71). In 24 cases the stent was placed via the major papilla, 11 were placed via the minor papilla. The median interval between stent placement and removal was 86 days (13–252) with median follow up of 22 months (3–33). One patient developed a Santorini duct abscess, which precipitated early stent removal but was otherwise managed conservatively. One instance of retrograde stent migration was noted and was managed endoscopically. 20 (57%) patients reported a complete resolution of pancreatic pain, 10 (29%) a partial response and 5 (14%) no response. A concomitant cessation or decline in the use of opiate analgesia was demonstrated. Of the five non- responders, three proceeded to lateral pancreatojejunostomy – two of whom reported a full symptomatic response. <h3>Conclusion</h3> Placement of FC-SEMS into the pancreatic duct of patients with painful chronic pancreatitis appears to be feasible and safe and does not preclude subsequent surgical intervention. The lengthy follow up data presented suggests that this endoscopic approach may be more effective than would be expected from historical studies of the use of plastic pancreatic duct stents. A controlled trial is warranted. <h3>Disclosure of Interest</h3> None Declared
Inside-Out Signaling through ADAP Is Required for VWF-GPIb-IX-V Mediated Integrin AIibb3 Activation.
Authors: Ana Kasirer-Friede, Barry P. Moran, Jennifer Nagrampa-Orje, Ken Swanson, Burkhart Schraven, Ben Neel5, Zaverio M. Ruggeri, Sanford J. Shattil
Journal: Blood (2005)
Intra-Lineage Phenotypic Switch in T-Cell Prolymphocytic Leukemia.
Authors: Nnenna Osuji, Ilaria Del Giudice, Estella Matutes, Vasantha Brito-Babapulle, Alison Morilla, Kwasi Owuso-Ankomah, Ricardo Morilla, Daniel Catovsky
Journal: Blood (2004)
R-CHOP vs R-mini-CEOP in Elderly Patients with Diffuse Large B Cell Lymphoma: An Interim Report from Intergruppo Italiano Linfomi (IIL).
Authors: Francesco Merli, Umberto Vitolo, Stefano Luminari, Patrizio Mazza, Caterina Stelitano, Giuseppe Rossi, Luca Baldini, Fiorella Ilariucci, Alessandro Levis
Journal: Blood (2005)
Long Term Clinical Outcomes in Patients with Massive Splenomegaly and Non-Hodgkin's Lymphoma Treated with Splenectomy.
Authors: Jacob Smeltzer, Thomas M Habermann, Taner Timucin, David Nagorney, Kay Ristow, Joseph P Colgan, Thomas E. Witzig, William Harmsen, Seth Slettedahl, John Donohue
Journal: Blood (2012)